Ignite Creation Date:
2024-05-05 @ 4:46 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00311740
Status:
COMPLETED
Last Update Posted:
2017-02-23
First Post:
2006-04-04
Brief Title:
A Study of VAH631 in Patients With Essential Hypertension Factorial Study
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Multi-center Factorial Study to Evaluate Efficacy Safety of 8 Wks Treatment With VAH631 Valsartan 40 80 mg and Hydrochlorothiazide 625 125 mg Combined Alone in Essential Hypertensive Patients - Double-blind Study of VAH631 in Patients With Essential Hypertension Factorial Study
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the effect of the fixed combination of valsartanhydrochlorothiazide HCTZ on blood pressure reduction with valsartan and HCTZ alone and whether the combination treatments are safe and well tolerated The study aims to establish a dose response relationship for both monotherapies and the combinations
This study is being conducted in Japan
This study is being conducted in Japan
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None